EDAP TMS

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EDAP TMS reports Q1 revenue growth and FDA breakthrough designation

EDAP TMS reported solid revenue growth in Q1 2024, driven by strong international placements and advancements in Focal One technology. While facing financial challenges, the company is strategically positioned to benefit from the expanding HIFU market and upcoming regulatory milestones. Opportunities lie in market expansion, new study data releases, and continued engagement with regulatory bodies.

EDAP TMS reports strong Q2 earnings, poised for market expansion

EDAP TMS delivered robust performance in Q2 2024, driven by revenue growth and advancements in key medical programs.
While facing challenges in profitability and expenses, the company is strategically positioned to capitalize on market opportunities.
Investments in research, management, and clinical trials signal a proactive approach towards sustainable growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDAP continues to rate higher in 2023. Positive phase 2 data investigating HIFU in rectal endometriosis adds another inflection point for investors to work by.

EDAP: Potential Crossover Of HIFU To Endometriosis Additional Inflection Points

Focal One ® HIFU treatment resulted in significant improvements in endometriosis symptoms  and quality of life (QoL) Positive safety profile with 9 6 . 7 % of patients with no or non- significant adverse events

EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal Endometriosis

Company preliminarily reports nine Focal One Placements in the U.S. , including seven sales

EDAP Announces Record Q4 US Focal One Placements

LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company's U.S. subsidiary. During his extensive career, Mr. Mobeck has demonstrated significant leadership expertise in driving transformational business growth while establishing a track record of creating lasting shareholder value.

EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company's U.S. Subsidiary

LYON, France, November 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has received approval from French authorities to initiate a Phase 3 randomized, controlled clinical trial evaluating Focal One high intensity focused ultrasound (HIFU) as a potential treatment for rectal deep infiltrating endometriosis.

EDAP Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis

EDAP TMS S.A. (EDAP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

EDAP TMS S.A. (EDAP) Is a Great Choice for 'Trend' Investors, Here's Why

ACRES Commercial Realty Corp.

Hyatt Hotels

ACR, EDAP and H made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 21, 2022.

Best Momentum Stocks to Buy for November 21st

LYON, France, November 21, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today that Marc Oczachowski, Chief Executive Officer, is scheduled to deliver a company presentation and host investor 1x1 meetings at the Piper Sandler 34th Annual Healthcare Conference, which is being held November 29 – December 1, 2022, in New York City.

EDAP to Present at the Piper Sandler 34th Annual Healthcare Conference

EDAP TMS S.A. (NASDAQ:EDAP ) Q3 2022 Earnings Conference Call November 17, 2022 8:30 AM ET Company Participants John Fraunces - LifeSci Advisors, IR Marc Oczachowski - CEO and Chairman of the Board of Directors Ryan Rhodes - CEO, EDAP US Francois Dietsch - CFO Conference Call Participants Michael Sarcone - Jefferies Jason Bednar - Piper Sandler Frank Takkinen - Lake Street Capital Markets Sean Lee - H.C.

EDAP TMS S.A. (EDAP) Q3 2022 Earnings Call Transcript

LYON, France, November 16, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the third quarter 2022.

EDAP Reports Third Quarter 2022 Results

Here is how EDAP TMS S.A. (EDAP) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.

Is EDAP TMS (EDAP) Stock Outpacing Its Medical Peers This Year?

EDAP TMS (EDAP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for EDAP TMS (EDAP)

If you are looking for stocks that are well positioned to maintain their recent uptrend, EDAP TMS S.A. (EDAP) could be a great choice.

Here's Why Momentum in EDAP TMS S.A. (EDAP) Should Keep going

Company to host conference call and webcast on Thursday , November 17 th at 8:30 am EDT

EDAP TMS SA to Announce Third Quarter 2022 Financial Results on Wednesday, November 16th, 2022

Final rule significantly raises Medicare reimbursement to U.S. hospital s performing a Focal One HIFU prostate ablation procedure

EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY23

EDAP TMS S.A. (EDAP) saw its shares surge in the last session with trading volume being higher than average.

EDAP TMS S.A. (EDAP) Moves 7.3% Higher: Will This Strength Last?

September 29, 2022 @ 8 AM ET Langham Hotel, NYC

EDAP TMS Hosting Urology Expert Panel and Live Focal One® Technology Demonstration

LYON, France, September 22, 2022 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced that the price of its public offering of its American Depositary Shares (“ADSs”), which commenced on September 22, 2022, has been set today at $7.50 per ADS, before underwriting discounts and commissions, and that the number of offered ADSs is 2,666,667. In addition, Jefferies LLC has been granted a 30-day over-allotment option to purchase up to an additional 400,000 ADSs on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, are expected to be approximately $20,000,003. The closing of the offering is expected to occur on September 27, 2022, subject to customary closing conditions.

EDAP Announces Pricing of Public Offering of American Depositary Shares

LYON, France, September 22, 2022 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced a public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.

EDAP Announces Proposed Public Offering of American Depositary Shares

Here is how EDAP TMS S.A. (EDAP) and Indivior PLC (INVVY) have performed compared to their sector so far this year.

Is EDAP TMS (EDAP) Outperforming Other Medical Stocks This Year?

EDAP TMS S.A. (NASDAQ:EDAP ) Q2 2022 Earnings Conference Call August 25, 2022 8:30 AM ET Company Participants John Fraunces - LifeSci Advisors, IR Marc Oczachowski - CEO & Chairman of the Board of Directors Ryan Rhodes - CEO, EDAP US Francois Dietsch - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Jason Bednar - Piper Sandler Swayampakula Ramakanth - H.C.

EDAP TMS S.A. (EDAP) Q2 2022 Earnings Call Transcript

LYON, France, August 24, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the second quarter 2022.

EDAP Reports Second Quarter 2022 Results

The placement of new Focal Ones got off to a good start this year and a filled-up pipeline is promising more, boosted by a big reimbursement improvement for Medicare. Reimbursement for Medicare patients' procedures almost doubled in July, significantly improving the economics for the Focal One.

EDAP's Focal One Revenue Is Set To Accelerate

Company to host conference call and webcast on Thursday , August 25 th at 8:30 am EDT

EDAP TMS SA to Announce Second Quarter 2022 Financial Results on August 24th, 2022

EDAP TMS S.A. (EDAP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.

News for EDAP TMS Stock (EDAP)